Deals this week: Takeda Pharma, Pfizer, Huons Global

7th July 2016 (Last Updated July 7th, 2016 18:30)

Takeda Pharma and Altos Therapeutics have entered a definitive agreement to jointly develop a treatment for gastroparesis (GP).

Pfizer

Takeda Pharma and Altos Therapeutics have entered a definitive agreement to jointly develop a treatment for gastroparesis (GP).

According to the agreement, the two partners will develop the compound ATC-1906 and its dopamine receptor antagonist mechanism of action. Takeda Pharma will also have an exclusive option to acquire Altos Therapeutics.

Takeda Pharma will make an upfront payment to Altos Therapeutics and assume control over the development and commercialisation of ATC-1906, while Altos Therapeutics will be eligible for additional payments linked with key commercial milestones of the compound.

Pfizer has announced that it will acquire majority assets of BIND Therapeutics for a consideration of $20m.

Following the transaction, Pfizer will acquire all the assets and certain contractual liabilities of BIND.

The transaction is expected to be completed in the third quarter of this year.

Huons Global has announced that it will raise gross proceeds of $250.3m through public offering of its 4,959,779 common stock shares.

The subscription period for the offering will start from 22 July and complete by 10 August.

"Following the transaction, Pfizer will acquire all the assets and certain contractual liabilities of BIND."

Nantong Jinghua Pharma plans to raise up to $165.5m of funds through a private placement of its shares.

The company intends to invest the funds for the acquisition of Alpha Pharma.

CStone Pharma has raised $150m in a series A venture financing round. The financing round was led by Oriza Seeds Venture Capital Consultancy and WuXi Healthcare Ventures.

The company plans to use the funds to further advance its clinical-stage programmes and work on new innovations to treat patient in China and all over the world.


Image: Pfizer has announced that it will acquire majority assets of BIND Therapeutics. Photo: courtesy of Neruru via Wikipedia.